{"id":"nct:NCT06417008","kind":"trial","title":"A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer","authors":["Hansoh BioMedical R&D Company"],"author_count":1,"year":2024,"published":"2024-05-16","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT06417008","source_url":"https://clinicaltrials.gov/study/NCT06417008","archive_url":"https://space-kitty.com/papers/nct:NCT06417008","updated":"2025-08-01","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of this study is to assess the safety, efficacy, pharmacokinetics and immunogenicity of HS-20117 combined with Aumolertinib in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \\[Exon 19del\\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Non-Squamous Non-Small Cell Lung Cancer"],"details":{"acronym":null,"status":"RECRUITING","phase":"PHASE2, PHASE3","study_type":"INTERVENTIONAL","enrollment":1080,"sponsor":"Hansoh BioMedical R&D Company","conditions":["Non-Squamous Non-Small Cell Lung Cancer"],"interventions":["DRUG: HS-20117","DRUG: Aumolertinib"],"start_date":"2024-05-28","start_date_type":"ACTUAL","primary_completion_date":"2026-06-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}